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and intravenous enoxaparin (30 mg) followed by angiography within 3-12 hs of randomis-
ation and adequate revascularisation (culprit artery plus non-culprit severe diseased
arteries threatening functionally important areas) with stenting or surgery. When T failed
(TIMI flow grade 0 or 1) abciximab was given before stenting. Heparin was stopped in
both groups after PCI. The co-primary endpoints were: infarct size (CK-MB mass, cTnT
release), left ventricle 6-week angiographic evolution (volume, ejection fraction, wall
motion index) and myocardial reperfusion (normalization of ST at 3 and 6 hs). The inci-
dence of cardiac and non-cardiac events was also compared.
Results: There were no differences between primary PCI and facilitated strategies in
terms of infarct size (CK-MB mass: 4768±3734 vs 4602±3371 ug/Lxh, p= 0.76; cTnT:
275±211 vs 242±156 ug/Lxh, p=0.55), left ventricular ejection fraction at 6 weeks (56±13
vs 56±12%, p= 0.9); wall motion index at six weeks (-1.1±0.6 vs -1.2±0.4, p= 0.1) and
myocardial perfusion (normalization of ST at 3 hs: 47 vs 46%, p= 0.83). However, in facil-
itated pts the incidence of complete ST resolution at 6 hs was higher (43 vs 61%,
p=0.03), and the rate of cardiac events at six month tends to be lower (death, reinfarction
or revascularization: 14% vs 9%).
Conclusions: According to the results of the GRACIA-2 trial, the strategy of performing
facilitated intervention is as safe as optimal primary PCI for pts with STEAMI. Results
also suggest that both strategies have equivalent efficacy in restoring myocardial perfu-
sion, preserving left ventricular size and function and beneficing clinical outcome.
1118-79 Drag Reduction by Polymer Infusion: A New Mechanism 
to Enhance Microcirculatory Perfusion for the Treatment 
of Ischemia
John J. Pacella, Erxiong Lu, Joan Gretton, David Fischer, Marina V. Kameneva, 
Flordeliza S. Villanueva, University of Pittsburgh, Pittsburgh, PA
Background: In the setting of severe, flow-limiting coronary artery stenosis, we have
previously shown that drag-reducing polymers (DRPs), which are unique, blood-soluble
macromolecules, have therapeutic potential because they further lower microvascular
resistance and enhance perfusion, even after autoregulation is exhausted. In bench stud-
ies involving rigid tubes, DRPs reduce resistance by altering the hydrodynamic proper-
ties of blood flow. Whether changing blood rheology is their mechanism of action in vivo,
or whether it also involves vasodilation is unclear. To test the hypothesis that DRPs
decrease resistance and increase blood flow without causing vasodilation, we examined
the microcirculation of the cremaster muscle in rats using intravital microscopy. Methods:
Catheters were placed in the carotid artery for pressure measurement in 13 anesthetized
rats. A flow probe was placed around the abdominal aorta. The cremaster muscle was
exposed and mounted on a microscope. Red blood cell (RBC) velocity and vessel diame-
ters were measured in arterioles (A), venules (V), and capillaries (C) pre- and post- intra-
venous DRP (polyethylene oxide, 1PPM). Vascular resistance was calculated as mean
arterial pressure/aortic flow. In 5 controls, topical nipride was applied to the cremaster to
confirm measurable vasoactivity in our model. Results: Arteriolar diameter increased
18±4% (p<0.03) after topical nipride in controls. DRP increased aortic flow (7.4±1.0 vs.
5.0±0.6 mL/min, p<0.002) and decreased vascular resistance (14.2±1.7 vs. 23.5±2.7
mmHg-min/mL, p<0.01). There was no significant change in diameter at any microvascu-
lar level in association with this resistance reduction. DRP increased RBC velocity in the
A (13.0±0.8 vs. 11.4±0.6 mm/sec, p<0.04), V (10.3±0.4 vs. 8.5±0.6 mm/sec, p<0.003)
and C (149±34 vs. 103±31 µm/sec, p<0.02). Conclusions: DRPs lower vascular resis-
tance and increase flow without causing vasodilation. The rise in flow is accompanied by
an increase in microvascular RBC velocity. Primary enhancement of microvascular perfu-
sion through modulation of the rheological properties of blood represents a promising,
novel therapeutic strategy for ischemic syndromes.
1118-80 Effects of Intracoronary Low-Dose Enalaprilat on QT 
Dynamicity in Patients Undergoing Direct Percutaneous 
Coronary Intervention for Acute Myocardial Infarction
Hendrik Bonnemeier, Ulrich Schaefer, Thomas Kurz, Uwe Wiegand, Jasmin Ortak, Hugo 
A. Katus, Gert Richardt, University Luebeck, Medical Clinic II, Luebeck, Germany
Experimental data suggest that ACE inhibition results in an increased ventricular electri-
cal stability in acute myocardial infarction (AMI). As electrical stability is largely depen-
dent on ventricular repolarization, we sought to determine the impact of low-dose
intracoronary application of enalaprilat (EN) as an adjunct to direct PCI on the QT/RR
relationship in AMI.
Methods and Results: Twenty-two patients with AMI who underwent direct PCI (TIMI 3
flow) were randomized to EN (50µg) or saline (SA), given immediately after reperfusion.
On hospital admission a 24-hour-Holter-ECG was initiated. Slopes of the linear QT/RR
regression were determined for the time intervals before reperfusion and after reperfu-
sion. A total of 6 patients in the EN group and 6 patients in the SA group had valid Holter-
ECGs for QT analysis. Mean RR interval and QT interval were not significantly different
between the EN and the SA groups before and after PCI. There were also no significant
differences regarding QT/RR slopes between EN and SA groups before PCI. After PCI,
QT/RR slopes significantly decreased in the EN group, whereas there were no significant
alterations in the SA group.
Conclusion: Intracoronary EN therapy as an adjunct to direct PCI significantly
decreases QT/RR slopes, suggesting a normalization of the coupling between heart rate
and repolarization by improving electrical restitution. Thus, our findings offer new insights
into possible beneficial effects of ACE inhibition on electrical stability in AMI. 
1118-81 The Impact of Abciximab on Final Infarct Size and Left 
Ventricular Function of Patients With Acute Myocardial 
Infarction Undergoing Primary Stenting: Insights From 
the Abciximab and Carbostent Evaluation (ACE) Trial
Guido Parodi, Angela Migliorini, Roberto Sciagrà, Gentian Memisha, Renato Valenti, 
David Antoniucci, Careggi Hospital, Florence, Italy
OBJECTIVES: We sought to evaluate the impact of abciximab, as adjunctive therapy to
routine infarct-related artery (IRA) stenting, on effectiveness of myocardial reperfusion.
BACKGROUND: The impact of abciximab on left ventricular (LV) volumes and function of
patients with acute myocardial infarction (AMI) undergoing IRA stenting is not yet
defined. METHODS: Four hundreds unselected patients with AMI were randomised 1:1
to IRA stenting alone or stenting plus abciximab. One- month gated 99m-Tc Sestamibi
SPECT had to be performed in a pre-specified subgroup of 250 patients to evaluate inf-
arct size and LV volumes. RESULTS:Out of the 250 patients planned for the scintigraphic
assessment, 8 died within the first month, 12 dropped out of the study protocol, 13 were
excluded because gated acquisition was precluded by arrhythmias or technical reasons,
and 35 had a previous myocardial infarction preventing the index infarct size evaluation.
Thus, 182 patients represent the final study group (99 patients were randomized to abcix-
imab therapy and 83 to stenting alone). There were no differences in the baseline clinical
and angiographic characteristics, and in discharge therapy between the 2 groups. In the
abciximab group infarct size was smaller than in stenting alone group (14.3±11.7 versus
19.1±13.0 %; p=0.01), resulting in smaller LV end-diastolic volume index (57.8±20.0 ver-
sus 64.6±20.8 mL/m2; p=0.03), and LV end-systolic volume index (31.7±17.4 versus
37.5±18.6 mL/m2; p=0.03). One-month LV ejection fraction was significantly higher in
patients randomized to abciximab, as compared to stenting alone (47.4±11.3 versus
43.9±11.7 %; p=0.04). Reinfarction within 30 days occurred in 3 (4%) of patients of the
stenting alone group as compared to none of the abciximab group (p=0.056). After
excluding the 3 patients who experienced a reinfarction, the beneficial effect of abciximab
on LV volumes and function still persists. CONCLUSIONS: The use of abciximab, as a
standard adjunctive therapy to IRA, leads to the reduction in infarct size, resulting in
smaller 1-month LV volumes and better LV function. The effect is not explained by the
lower reinfarction rate.
1118-82 Distinct Modes of Cardiovascular Death Associated 
With Impaired Epicardial and Myocardial Perfusion 
Following Fibrinolysis for ST Elevation Myocardial 
Infarction
Stephen D. Wiviott, Marc S. Sabatine, David A. Morrow, Raphaelle Dumaine, Sabina A. 
Murphy, Kieth E. Boundy, Christopher P. Cannon, C. Michael Gibson, Brigham and 
Women's Hospital, Boston, MA
Background: Despite fibrinolysis for ST-elevation MI (STEMI), a significant mortality
remains. A comprehensive analysis of cause of death and angiographic features could
provide important information for therapeutic decision-making and understanding patho-
pysiology.
Methods: 3683 patients from an angiographic database STEMI fibrinolysis trials were
analyzed. 180 deaths (4.9%) were observed. Angiographic features were measured by a
blinded core lab.
Results: Causes of death included: CHF/Shock (22%), Stroke/ICH (18%), dysrhythmia
(16%), cardiac rupture (13%), MI (12%), other cardiac (7%), hemorrhage (3%). Those
with cardiac death compared to survivors were less likely to have TIMI flow grade (TFG)
2-3 (p<0.001) and TIMI Myocardial Perfusion Grade (TMPG) 2-3 (p=.004); had higher
Corrected Frame Counts (CTFC, 68 vs.52, p<0.001), and were more likely to have 3 ves-
sel CAD (p=0.001) or thrombus (p=0.001). Among cardiac deaths, TFG 0-1, higher
CTFC, were associated with CHF/Shock (figure); TFG 0-1 and TMPG 0-1 were associ-
ated with dysrhythmia (figure) and cardiac rupture (p<0.05). There were no angiographic
correlates of CVA/hemorrhage.
Conclusions: Impairment of epicardial and myocardial perfusion were associated with
cardiovascular mortality. Angiographic features differed among causes of death. These
angiographic correlates with mortality may aid in understanding the limitations of reperfu-
sion therapy and the search for new modalities to reduce mortality in STEMI. 
JACC March 3, 2004 ABSTRACTS - Myocardial Ischemia and Infarction  291A
M
yocardial Ischem
ia and Infarction
1118-83 Pathological Features Found Postmortem in 53 Patients 
With Cardiac Rupture Complicating Acute Myocardial 
Infarction
Satoshi Yasuda, Yasuhide Asaumi, Hiroyuki Okumura, Yoritaka Otsuka, Isao Morii, 
Atsushi Kawamura, Chikao Yutani, Hiroshi Nonogi, Shunichi Miyazaki, National 
Cardiovascular Center, Osaka, Japan
Background: Cardiac rupture is responsible for about 15% of all in-hospital deaths
among patients with acute myocardial infarction (AMI). However, information regarding
the clinical profile and pathological features of this fatal complication is limited.
Methods: We studied 53 consecutive patients with AMI (M/F; 32/21, age; 73±7
[mean±SD] years), who died of ventricular septal and free wall rupture between 1978 and
2002. The diagnosis was made based on postmortem histological examination. Forty-
two patients (80%) were without previous infarction and 44 patients (84%) were hyper-
tensive.
Results: Cardiac rupture occurred acutely within 48 hours of AMI onset in 20 patients
(38%). Also, it occurred 6-8 days after the onset of AMI in 17 patients (32%), in whom
immunohistochemical studies revealed accumulation of inflammatory cells and activation
of matrix metalloproteinases at the rupture site. AMI-related artery was the left anterior
descending artery in 37 patients (70%), the right coronary artery in 13 patients (25%)
and the left circumflex artery in 3 patients (5%). In most patients (n=48, 91%), the AMI-
related vessel was totally or subtotally occluded. Since 1993, the era in which the reper-
fusion therapy has been developed, the total number of rupture patients has been
decreasing, but the percentage of those with hemorrhagic infarction has been increasing;
1978–82, n=12 (17%); 1983-87, n=14 (29%); 1988-92, n=14 (36%); 1993-97, n=7 (57%);
1998-2002, n=6 (50%).
Conclusions: These findings indicate the potential importance of revascularization of
the AMI-related artery to reduce the risk of cardiac rupture. Histologically, sustained
inflammatory responses with metalloprotease activation may contribute to modulating the
wound-healing process following infarction.
1118-84 Is the Timing of Coronary Artery Bypass Graft Surgery 
Following Acute Myocardial Infarction Associated With 
a Difference in Mortality?
Michael Mack, Marc Katz, Aaron Kugelmass, J. James Zocco, Timonthy Wolfgang, 
Thomas Christopher, Edmund Becker, Steven Culler, April Simon, Emory University, 
Atlanta, GA, CRSTI, Dallas, TX
Background: This study examines association between operative and predicted mortal-
ity rates and the length of time between a preoperative myocardial infarction (MI) and cor-
onary artery bypass graft surgery (CABG) in patients treated in community hospitals.
Methods: The study sample consists of 5,465 consecutive patients who underwent
CABG only in one of 18 community hospitals. Logistic regression analysis was utilized to
determine if selected time intervals ( 21 days) between a preoperative MI and CABG
were statistically associated with operative mortality after controlling for 30 demographic,
procedural and cardiac risk factors.
Results: Approximately 42% of the sample had an MI prior to CABG. Patient’s whose
CABG was performed within the first 24 hours had significantly higher mortality rates
than those observed for patients whose CABG was delayed by at least 24 hours (see
table). Controlling for demographic, procedural and cardiac risk factors, patient’s whose
CABG was performed within the first 24 hours were 2.7 times (p=0.024) more likely to die
during their hospitalization than patients having surgery between 1 and 7 days after their
MI.
Conclusions: Operative mortality is highest if CABG is performed within the first 24 hrs
of MI, but there is no difference between any of the other MI groups (1-7 days, 8-21 days,
or > 21 days). Further research needs to assess the clinical imperative for surgery within
the first 24 hrs. 
1118-101 Congestive Heart Failure and Cardiogenic Shock 
Complicating Acute Myocardial Infarction Have High 
Mortality and Are Associated With Intense Inflammatory 
Response: Results From the CARDINAL Trials
Rafael Valencia, Pierre Theroux, Christopher B. Granger, Kenneth W. Mahaffey, Taissa 
Gudaye, Kevin Malloy, W. Douglas Weaver, Thomas G. Todaro, Christopher F. Mojcik, 
Paul W. Armstrong, Judith S. Hochman, New York University Medical Center, New York, 
NY
There are limited data on the development, clinical correlates, role of inflammation and
outcomes of CHF and cardiogenic shock (CS) complicating acute ST-elevation MI
(STEMI) in the reperfusion era.
We analyzed data from The Complement and ReDuction of Infarct size after Angioplasty
or Lytics (CARDINAL) program which included fibrinolytic and primary percutaneous cor-
onary intervention (PCI) trials investigating adjunctive pexelizumab, a monoclonal anti-
body against C5 complement, in the management of STEMI. The characteristics and
outcomes of 1903 enrolled patients and a subset of 350 PCI patients with serial inflam-
matory markers and proBNP levels were evaluated.
New or worsening CHF or CS developed in 3% and 4% of patients respectively. Patients
who developed CHF or CS presented with a greater prevalence of diabetes mellitus
(p=0.003). There was an association of increasing heart rate (p<0.001) and decreasing
systolic blood pressure (p<0.001) on presentation and increasing infarct size (area under
the curve for CK MB thru 72 hrs) (p<0.001) with the development of CHF or CS. White
blood cell count at presentation was higher in the group that developed CS (p=0.006).
Higher levels of IL-6, TNF alpha, hsCRP, and proBNP were seen in patients who pre-
sented in CHF or CS. Patients who presented to the hospital without CHF or CS but later
developed new CS had significantly higher levels of IL-6, TNF alpha, and proBNP at pre-
sentation, 24 hours and 72 hours after presentation compared to patients who did not
develop CS. The most striking difference was seen with IL-6 with average values at time
0, 24 and 72 hours of 19, 367, and 199 pg/mL in patients who presented without CHF or
CS but developed new CS compared to patients who did not develop CS whose values
were 11, 50, and 29 pg/mL respectively (p<0.001). Mortality in patients who developed
CS was 61% compared with 13% in patients who developed CHF and 5% in patients
without the development of CHF or CS (p<0.001).
Despite reperfusion therapy, CHF and CS continue to complicate acute STEMI and are
associated with high mortality rates. CHF and to a larger extent, CS, are associated with
a marked inflammatory response which has potential diagnostic and therapeutic implica-
tions.
1118-102 Baseline White Blood Cell Count and Interleukin-6 
Levels Provide Complementary Prognostic Information 
in Acute Myocardial Infarction: Results From the 
CARDINAL Trial
Manesh R. Patel, Kenneth W. Mahaffey, Paul W. Armstrong, W. Douglas Weaver, Gudaye 
Tasissa, Judith S. Hochman, Thomas G. Todaro, Kevin J. Malloy, Thomas H. Parish, 
Scottt Rollins, Pierre Theroux, Wiltold Ruzyllo, Jose C. Nicolau, Christopher B. Granger, 
Duke Clinical Research Institute, Durham, NC
Background: Inflammation plays an important role in pathophysiology of acute coronary
syndromes.
Methods: The relationships between baseline WBC count, interleukin-6 (IL6) levels in a
subset of patients (n=328), and their association with outcomes were analyzed using
data from two trials in the CARDINAL program evaluating pexelizumab (antibody to com-
plement factor C5) in patients with ST elevation myocardial infarction undergoing fibrinol-
ysis (n=934) or primary PCI (n=960). Infarct sizes determined by CKMB area under the
curve and 90-day mortality were analyzed.
Results: Higher WBC counts (highest quartile vs. lowest quartile) at presentation were
associated with younger age (median 56 vs. 62 years), higher proportion of anterior inf-
arcts (82.9% vs. 76.9%), and higher proportion with Killip Class > 1 (22.6% vs. 11.2%)
respectively. Higher WBC count was also associated with larger infarct size (CKMB 5690
vs. 2882 [ng/mL] • h) and development of congestive heart failure and shock (6.6% vs.
2.6%). Mortality at 90-days was significantly related to WBC count (figure, p
value=0.017). Median IL-6 levels tracked with baseline WBC count, highest vs. lowest
quartile(Q4-16 ng/dl vs.Q1-8.3ng/dl IL-6), and subsequent outcomes.
Conclusion: WBC count was directly related to infarct size and mortality. A marker of
inflammation, IL-6 tracked with WBC count and outcomes. The baseline WBC count is a
simple marker of inflammation that provides prognostic information. 
Mortality Rates From Time of MI to CABG
No MI < 24 Hrs. 1-7 Days 8-21 Days > 21 Days
Patients 3,213 103 957 217 975
Operative Mortality 1.7% 19.4% 3.7% 2.8% 3.3%
Predicted Mortality 2.1% 10.7% 4.0% 4.9% 3.3%
